CNS Pharmaceuticals, Inc. Logo

CNS Pharmaceuticals, Inc.

Biotech developing drugs that cross the blood-brain barrier for brain and CNS cancers.

CNSP | US

Overview

Corporate Details

ISIN(s):
US18978H1023
LEI:
Country:
United States of America
Address:
2100 WEST LOOP SOUTH, 77027 HOUSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CNS Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for primary and metastatic cancers of the brain and central nervous system. The company's primary therapeutic focus is on glioblastoma multiforme (GBM), an aggressive and often incurable form of brain cancer. Its development pipeline features anti-cancer drug candidates, including its lead drug Berubicin, which are designed to cross the blood-brain barrier to effectively target brain malignancies. CNS Pharmaceuticals aims to advance transformative therapies through pioneering research to improve patient outcomes.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all CNS Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CNS Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CNS Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

INCYTE CORP Logo
Develops proprietary therapeutics for serious unmet needs in oncology and inflammation.
United States of America
INCY
Indivior PLC Logo
Develops pharmaceuticals for opioid use disorder, addiction, and serious mental illnesses.
United Kingdom
INDV
Infant Bacterial Therapeutics Logo
Develops live bacterial medicines to prevent rare, severe gut diseases in premature infants.
Sweden
IBT
Inhibikase Therapeutics, Inc. Logo
Develops kinase inhibitors to treat neurodegenerative diseases like Parkinson's.
United States of America
IKT
Inhibrx Biosciences, Inc. Logo
Clinical-stage biopharma developing novel biologic therapies for life-threatening cancers.
United States of America
INBX
InMed Pharmaceuticals Inc. Logo
Develops cannabinoid drugs for unmet medical needs and supplies rare cannabinoids for B2B wellness.
United States of America
INM
Inmune Bio, Inc. Logo
Develops immunotherapies reprogramming innate immunity for cancer, Alzheimer's, and inflammation.
United States of America
INMB
Innate Pharma Logo
Clinical-stage biotech developing NK cell-engaging antibodies for cancer immunotherapy.
France
IPH
INNOGENE Co., Ltd. Logo
Develops research-driven anti-aging solutions for skin regeneration and hair follicle formation.
South Korea
344860
INOVIO PHARMACEUTICALS, INC. Logo
Develops DNA medicines delivered via smart devices for cancer, HPV, and infectious diseases.
United States of America
INO

Talk to a Data Expert

Have a question? We'll get back to you promptly.